# Antibody Response to COVID-19 Vaccines in Liver Disease Patients

> **NCT04775069** · PHASE4 · COMPLETED · sponsor: **Humanity & Health Medical Group Limited** · enrollment: 232 (actual)

## Conditions studied

- Chronic Liver Disease

## Interventions

- **BIOLOGICAL:** BNT162b2
- **BIOLOGICAL:** CoronaVac
- **BIOLOGICAL:** AZD1222

## Key facts

- **NCT ID:** NCT04775069
- **Lead sponsor:** Humanity & Health Medical Group Limited
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-21
- **Primary completion:** 2023-09-30
- **Final completion:** 2023-09-30
- **Target enrollment:** 232 (ACTUAL)
- **Last updated:** 2023-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04775069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04775069, "Antibody Response to COVID-19 Vaccines in Liver Disease Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04775069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*